Table 2.
Details of durations used for the main criterion in each group.
| Variable | Overall | Placebo Group | Timolol Group | P-value | |
|---|---|---|---|---|---|
| Total epistaxis duration before treatment | |||||
| M − 3 | n | 58 | 29 | 29 | 0.47 |
| median (min − max) | 108.5 (0–825) | 83 (0–545) | 143 (22.58–825) | ||
| Mean (SD) | 172.47 (177.43) | 155.6 (150.97) | 189.33 (201.76) | ||
| M − 2 | n | 58 | 29 | 29 | 0.99 |
| median (min − max) | 122.5 (15–600) | 118 (15–600) | 129 (22.15–561) | ||
| Mean (SD) | 167.74 (139.12) | 172.1 (151.46) | 163.38 (128.13) | ||
| M − 1 | n | 58 | 29 | 29 | 0.97 |
| median (min − max) | 155.5 (0–580) | 128 (0–520) | 163 (12.5–580) | ||
| Mean (SD) | 183.04 (145.42) | 180.79 (146.39) | 185.29 (146.99) | ||
| Total epistaxis duration after treatment (3 months) | |||||
| M + 1 | n | 58 | 29 | 29 | 0.62 |
| median (min − max) | 125 (11–612) | 100 (14–505) | 143 (11–612) | ||
| Mean (SD) | 162.3 (137.13) | 154.42 (136.36) | 170.18 (139.84) | ||
| M + 2 | n | 58 | 29 | 29 | 0.54 |
| median (min − max) | 94 (6–605) | 95 (12–513) | 93 (6–605) | ||
| Mean (SD) | 171.95 (162.32) | 180.61 (160.99) | 163.29 (166.02) | ||
| M + 3 | n | 58 | 29 | 29 | 0.96 |
| median (min − max) | 109.5 (7–599) | 97 (7–475) | 126 (10.2–599) | ||
| Mean (SD) | 158.87 (146.98) | 147.89 (126.31) | 169.85 (166.66) | ||
| Mean epistaxis duration at 3 months | |||||
| Before treatment | n | 58 | 29 | 29 | 0.78 |
| median (min − max) | 136.5 (19.08–642.33) | 132 (24–555) | 141.67 (19.08–642.33) | ||
| Mean (SD) | 174.57 (144.72) | 169.5 (143.08) | 179.65 (148.71) | ||
| After treatment | n | 58 | 29 | 29 | 0.98 |
| median (min − max) | 123.17 (12.4–583.67) | 101.67 (14–491.67) | 125.33 (12.4–583.67) | ||
| Mean (SD) | 164.92 (141.94) | 162.06 (134.45) | 167.78 (151.39) | ||
| Difference Before - After | n | 58 | 29 | 29 | 0.81 |
| median (min − max) | −18.17 (−230.33–134.33) | −16.33 (−230.33–134.33) | −20 (−177.33–125) | ||
| Mean (SD) | −9.65 (68.61) | −7.44 (71.23) | −11.87 (67.08) | ||